21 October 2024
EMA/491267/2024
EMEA/H/C/004011

Public statement

Pemetrexed Sandoz (pemetrexed)

Withdrawal of the marketing authorisation in the European Union

On 9 October, the European Commission withdrew the marketing authorisation for Pemetrexed Sandoz (pemetrexed) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Sandoz GmbH, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pemetrexed Sandoz was granted marketing authorisation in the EU on 18 September 2015 for the treatment of malignant pleural mesothelioma and non-small cell lung cancer. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity in 2020. The product had not been marketed in the EU since 2024.

Pemetrexed Sandoz is a generic medicine of Alimta. There are other generic medicinal products of Alimta authorised and marketed in the EU.

The European Public Assessment Report (EPAR) for Pemetrexed Sandoz will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union